The company, which is based in Leuven, Belgium, is one of the largest independent European distributors of prostate seeds. Its main markets are Benelux and Portugal. Both parties have agreed not to disclose the purchase price.
Through the takeover, Eckert & Ziegler is acquiring BrachySolutions` customer base in Benelux, the United Kingdom, and Portugal, thereby securing its strong position in Europe as a manufacturer of seeds.
"By acquiring BrachySolutions, we are further honing our strategic focus. Our strategy centers on consolidating the market, cementing our market position in Europe, and creating synergies within our portfolio of solutions," said Dr. Harald Hasselmann, Managing Director of Eckert & Ziegler BEBIG and member of the Board of Directors.
"Eckert & Ziegler`s Berlin-made prostate implants stand for top quality. I believe firmly that our brachytherapy customers will continue to receive the best possible products and excellent service in the future," Luk Herremans, founder and Managing Director of BrachySolutions, added.
Brachytherapy is a medical treatment method that includes placing implants containing radioisotopes directly into tumor tissue. The local radiation provided by the implants leads to the destruction of cancer cells. Permanent brachytherapy is mainly used to treat prostate cancer.
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the treatment of cancer using brachytherapy, a special form of radiation therapy.
Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe. The company headquarters are in Belgium, with a production facility in Germany and subsidiaries throughout Europe, in the USA, India and Brazil.
